Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept Study

Trial Profile

Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary) ; Bevacizumab; Cisplatin; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IRAFU
  • Most Recent Events

    • 08 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2018 Results (n=32) assessing efficacy of anakinra in combination with bevacizumab and fluorouracil, folinic acid and cisplatin (FV5FU2), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top